Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06139094 · ClinicalTrials.gov registry record
MCG for Suspected INOCA Confirmed by Thermodilution-Derived CFR
A clinical trial, sponsored by Genetesis.
- Completed
- Registry status
- 48
- Enrollment target
NCT06139094 is a clinical trial that has completed, run by Genetesis. The registered enrollment target is 48 participants.
The verdict
NCT06139094 has completed, sponsored by Genetesis.
- COMPLETED
- Registry status
- 48 participants
- Enrollment target
Study Summary
This study will be an observational registry to investigate the ability of magnetocardiography (MCG) in determining the presence of myocardial ischemia with the absence of obstructive coronary artery disease, by using an invasive reference standard coronary flow reserve (CFR) measured using thermodilution for diagnosis. The device is a magnetocardiography (MCG) scanner named CardioFlux, which is paired with cloud processing software. A CardioFlux scan appointment shall last approximately 15 minutes in duration and include a patient questionnaire following the scan.
Interventions
- DEVICE CardioFlux Magnetocardiography
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2023-12-20 |
| Est. Completion | 2024-05-13 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06139094
The ClinicalTrials.gov registry entry for NCT06139094 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genetesis, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CardioFlux Magnetocardiography is the first listed.
NCT06139094 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06139094 about?
NCT06139094 is a clinical study titled "MCG for Suspected INOCA Confirmed by Thermodilution-Derived CFR". This study will be an observational registry to investigate the ability of magnetocardiography (MCG) in determining the presence of myocardial ischemia with the absence of obstructive coronary artery disease, by using an invasive reference standard coronary flow reserve (CFR) measured using thermodi...
What is the current status of trial NCT06139094?
This trial is currently completed. The enrollment target is 48 participants. The study started on 2023-12-20. Estimated completion is 2024-05-13.
What interventions are being tested in trial NCT06139094?
The interventions under investigation include: CardioFlux Magnetocardiography (DEVICE).
Who is sponsoring clinical trial NCT06139094?
This trial is sponsored by Genetesis, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.